Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc, No. 13-1306 (Fed. Cir. June 12, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This patent infringement case concerns a drug for the treatment of hepatitis B. After a four-day bench trial, the United States District Court for the District of Delaware found claim 8 of U.S. Patent No. 5,206,244 (’244 patent ) invalid as obvious. We af firm the district court’s invalidi- ty judgment for the reasons that follow. I. Appellant Bristol-Myers Squibb Co. ( BMS) owns the ’244 patent. C laim 8 of the ’ 244 patent is directed to a nucleoside analog composed of two regions: a carbocyclic ring and a guanine base.